AR126954A1 - METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS - Google Patents
METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTSInfo
- Publication number
- AR126954A1 AR126954A1 ARP220102366A ARP220102366A AR126954A1 AR 126954 A1 AR126954 A1 AR 126954A1 AR P220102366 A ARP220102366 A AR P220102366A AR P220102366 A ARP220102366 A AR P220102366A AR 126954 A1 AR126954 A1 AR 126954A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- receptor antagonists
- cgrp receptor
- treating psoriasis
- snhc
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 3
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 1
- 101100203601 Caenorhabditis elegans sor-3 gene Proteins 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos para tratar la psoriasis con uno o más antagonistas de receptores de CGRP y/o sus composiciones farmacéuticas. Tales métodos son útiles para tratar, mejorar, aliviar, proporcionar profilaxis o prevención, detener la progresión y/o reducir el riesgo de psoriasis en un sujeto mamífero, tal como un humano. En particular, los antagonistas del receptor de CGRP tales como los de fórmula (1), fórmula (2) y/o fórmula (1) son útiles en métodos para tratar la psoriasis en un sujeto que lo necesita, donde de un modo general A es CH; D es O, NCN o NSO₂alquiloC₁₋₃; E es N, CE o C; G, J y E juntos forman Aˣ; Aˣ es un heterociclo fusionado que tiene dos anillos fusionados con 5 a 7 miembros en cada uno de dichos anillos; m, n y p son cada uno 1; Q es (Sʸ)ₛR³; Q es un enlace, C(O), C(O)O o Q es Q o Q; Q es NH(Sʸ)ₛR³, NHC(O(Sʸ)ₛR³, NHC(O)O(Sʸ)ₛR³, NHC(O)NH(Sʸ)ₛR³, O(Sʸ)ₛR³, (Sʸ)₃NHR³, (Sʸ)ₛNHC(O)R³, (Sʸ)ₛNHC(O)OR³, (Sʸ)ₛNHC(O)NHR³ o (Sʸ)ₛOR³; U es CH₂ o NH; V es -N(R¹)(R²) o OR⁴; y en donde de un modo más preciso y detallado se describen en el presente documento.Methods are provided for treating psoriasis with one or more CGRP receptor antagonists and/or their pharmaceutical compositions. Such methods are useful for treating, ameliorating, alleviating, providing prophylaxis or prevention, arresting the progression and/or reducing the risk of psoriasis in a mammalian subject, such as a human. In particular, CGRP receptor antagonists such as those of formula (1), formula (2) and/or formula (1) are useful in methods of treating psoriasis in a subject in need thereof, where generally A is CH; D is O, NCN or NSO₂C₁₋₃alkyl; E is N, CE or C; G, J and E together form Aˣ; Aˣ is a fused heterocycle having two fused rings with 5 to 7 members in each of said rings; m, n and p are each 1; Q is (Sʸ)ₛR³; Q is a bond, C(O), C(O)O or Q is Q or Q; Q is NH(Sʸ)ₛR³, NHC(O(Sʸ)ₛR³, NHC(O)O(Sʸ)ₛR³, NHC(O)NH(Sʸ)ₛR³, O(Sʸ)ₛR³, (Sʸ)₃NHR³, ( Sʸ)ₛNHC(O)R³, (Sʸ)ₛNHC(O)OR³, (Sʸ)ₛNHC(O)NHR³ or (Sʸ)ₛOR³; U is CH₂ or NH; V is -N(R¹)(R²) or OR⁴; and where they are described in a more precise and detailed way in this document.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163240064P | 2021-09-02 | 2021-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126954A1 true AR126954A1 (en) | 2023-12-06 |
Family
ID=85412863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220102366A AR126954A1 (en) | 2021-09-02 | 2022-09-01 | METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR126954A1 (en) |
WO (1) | WO2023034466A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220862B2 (en) * | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
CN1674919A (en) * | 2002-08-12 | 2005-09-28 | 比克尔·斯韦恩森 | Use of cgrp antagonist compounds for treatment of psoriasis |
AU2003297694A1 (en) * | 2003-12-05 | 2005-08-12 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
EP3254681B1 (en) * | 2012-02-27 | 2019-06-19 | Bristol-Myers Squibb Company | N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt |
GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
CA3127328A1 (en) * | 2019-01-20 | 2020-07-23 | Biohaven Pharmaceutical Holding Company Ltd. | Cgrp antagonists for treating migraine breakthrough |
-
2022
- 2022-09-01 WO PCT/US2022/042282 patent/WO2023034466A1/en unknown
- 2022-09-01 AR ARP220102366A patent/AR126954A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023034466A1 (en) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR115885A1 (en) | COMPOUNDS DERIVED FROM 1H-PYRAZOLO [4,3-D] PYRIMIDINE AS AGONISTS OF THE TOLL TYPE 7 RECEPTOR (TLR7) AND THEIR USE IN COMBINATION WITH AN ANTI-CANCER IMMUNOTHERAPY AGENT | |
CO2020013601A2 (en) | Heterocyclic compounds as immunomodulators | |
AR110782A1 (en) | THIROSINAMIDE DERIVATIVES AS INHIBITORS OF RHO-QUINASA | |
AR010066A1 (en) | HETERO CYCLES AS INHIBITORS OF THE ACCESSION OF LEUKOCYTES AND VLA-4 ANTAGONISTS | |
AR109788A1 (en) | BENZO COMPOUNDS [B] THIOPHEN AS STING AGONISTS | |
AR112693A1 (en) | 3-PHENYL-5-TRIFLUOROMETILISOXAZOLIN-5-CARBOXAMIDES OF CYCLOPENTILCARBOXYLIC ACIDS AND ESTERS WITH HERBICIDAL EFFECT | |
AR010067A1 (en) | 5-RING HETERO CYCLES AS INHIBITORS OF THE ACCESSION OF LEUKOCYTES AND VLA-4 ANTAGONISTS | |
AR010065A1 (en) | HETEROCYCLIC COMPOUNDS AND THE USE OF THE SAME FOR THE PREPARATION OF USEFUL PHARMACS AS INHIBITORS OF THE ACCESSION OF LEUKOCYTES AND ANTAGONISTS OF THE VLA-4 | |
AR099367A1 (en) | INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON | |
ECSP19029835A (en) | CYCLIC TYROSINE PEPTIDE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE RECEPTORS AND | |
AR120823A1 (en) | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS | |
AR098776A1 (en) | ISOCROMENE DERIVATIVES AS INHIBITORS OF PHOSFOINOSITIDO-3 KINASES | |
AR092288A1 (en) | EP1 RECEIVER LIGANDS | |
AR103232A1 (en) | TGFbR ANTAGONISTS | |
AR114369A1 (en) | CYCLIC DINUCLEOTIDES AS ANTINEOPLASTIC AGENTS | |
AR113790A1 (en) | SUBSTITUTED IMIDAZOPYRIDINE AMIDES AND THEIR USE | |
AR115766A1 (en) | TYROSINAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | |
CL2018000231A1 (en) | Adamantilurea analogs as soluble epoxide hydrolase inhibitors | |
AR126954A1 (en) | METHODS FOR TREATING PSORIASIS WITH ONE OR MORE CGRP RECEPTOR ANTAGONISTS | |
CL2021001656A1 (en) | Imidazopyridine and imidazopyridine compounds and their uses. | |
AR114496A1 (en) | ANTIPROLIFERATION COMPOUNDS AND USES OF THEM | |
AR112794A1 (en) | HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE IN THE TREATMENT OF DISEASES INDUCED BY IDH MUTATIONS | |
PE20181328A1 (en) | ALKYL DIHYDROQUINOLINSULFONAMIDE COMPOUNDS | |
AR105460A1 (en) | SUBSTITUTED DERIVATIVES OF 2-PYRIMIDINE FURANO / TIENOCICLOALQUILAMINO AND ITS USE FOR THE CONTROL OF GROWTH OF NON-DESIRABLE PLANTS | |
AR122726A1 (en) | CEREBLON JUNCTION COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |